Insider Selling: Edwards Lifesciences Corp (EW) VP Sells 3,750 Shares of Stock

Edwards Lifesciences Corp (NYSE:EW) VP Donald E. Bobo, Jr. sold 3,750 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $127.54, for a total transaction of $478,275.00. Following the completion of the transaction, the vice president now directly owns 19,608 shares of the company’s stock, valued at approximately $2,500,804.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Donald E. Bobo, Jr. also recently made the following trade(s):

  • On Thursday, December 28th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock. The stock was sold at an average price of $114.08, for a total transaction of $604,624.00.
  • On Thursday, December 28th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock. The stock was sold at an average price of $114.08, for a total transaction of $604,624.00.
  • On Wednesday, November 29th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock. The stock was sold at an average price of $116.45, for a total transaction of $617,185.00.

Shares of Edwards Lifesciences Corp (EW) traded up $0.46 during mid-day trading on Tuesday, hitting $127.35. The stock had a trading volume of 1,016,167 shares, compared to its average volume of 1,381,409. The firm has a market capitalization of $26,750.00, a P/E ratio of 44.22, a PEG ratio of 1.86 and a beta of 0.63. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.41 and a current ratio of 1.81. Edwards Lifesciences Corp has a 1-year low of $89.20 and a 1-year high of $138.48.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.91 by $0.03. The business had revenue of $888.50 million for the quarter, compared to the consensus estimate of $868.45 million. Edwards Lifesciences had a return on equity of 27.69% and a net margin of 18.11%. The business’s quarterly revenue was up 15.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.75 earnings per share. sell-side analysts forecast that Edwards Lifesciences Corp will post 4.49 earnings per share for the current year.

Edwards Lifesciences announced that its Board of Directors has authorized a share repurchase plan on Thursday, December 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

A number of equities analysts recently commented on EW shares. Canaccord Genuity reissued a “buy” rating and issued a $135.00 price objective (down previously from $155.00) on shares of Edwards Lifesciences in a research note on Wednesday, October 25th. SunTrust Banks set a $124.00 price objective on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Barclays reduced their price objective on shares of Edwards Lifesciences from $120.00 to $118.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 25th. Morgan Stanley reduced their price objective on shares of Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating for the company in a research note on Thursday, October 26th. Finally, Deutsche Bank reduced their price target on Edwards Lifesciences from $122.00 to $115.00 and set a “hold” rating on the stock in a research report on Thursday, October 26th. Three investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. Edwards Lifesciences currently has an average rating of “Buy” and a consensus price target of $141.15.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its holdings in shares of Edwards Lifesciences by 2.2% during the fourth quarter. BlackRock Inc. now owns 15,410,737 shares of the medical research company’s stock valued at $1,736,943,000 after buying an additional 331,896 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Edwards Lifesciences by 45.7% during the fourth quarter. Bank of New York Mellon Corp now owns 7,580,924 shares of the medical research company’s stock valued at $854,444,000 after buying an additional 2,377,444 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Edwards Lifesciences by 12.1% during the fourth quarter. Alliancebernstein L.P. now owns 6,259,771 shares of the medical research company’s stock valued at $705,539,000 after buying an additional 675,216 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Edwards Lifesciences by 20.2% during the third quarter. Wells Fargo & Company MN now owns 2,548,282 shares of the medical research company’s stock valued at $278,553,000 after buying an additional 429,022 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Edwards Lifesciences by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 2,402,209 shares of the medical research company’s stock valued at $270,220,000 after buying an additional 93,049 shares during the last quarter. 81.11% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Edwards Lifesciences Corp (EW) VP Sells 3,750 Shares of Stock” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2018/02/13/insider-selling-edwards-lifesciences-corp-ew-vp-sells-3750-shares-of-stock.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply